A study presented Monday at the American Diabetes Association (ADA) Scientific Sessions found that one-third of those who initially screened positive for prediabetes or diabetes were able to bring their blood sugar down to normal levels after taking part in a workforce-based intervention.
The study by Quest Diagnostics, which involved a collaboration with the digital health provider Omada Health, shows promise for employer-based wellness programs that involve a 2-step process: screening for those at risk, and then offering an evidence-based program of lifestyle change and support for those whose health risks are revealed during screening.
Read More: https://www.ajmc.com/newsroom/quest-omada-health-collaboration-shows-onethird-in-workforce-study-reduced-risk-for-diabetes
When not researching systems to prevent strokes, you might find Silk Road Medical CEO Erica Rogers on the dance floor or acting in a staging of “The Sound of Music.”
Via: PR Newswire
Digital Therapeutics Pioneer Launches Comprehensive, Personalized Solution for Obesity-Related Chronic Disease
Compared with carotid endarterectomy, transcarotid artery revascularization was associated with similar in-hospital outcomes in patients with carotid stenosis, according to data presented at the Society for Vascular Surgery Vascular Annual Meeting.
Digital chronic disease management company Omada Health announced today the launch of new programs designed to support individuals with Type 2 diabetes and hypertension.
Silk Road Medical Announces Key Events for Society for Vascular Surgery 2018 Vascular Annual Meeting
Via: Business Wire
SUNNYVALE, Calif.--(BUSINESS WIRE)--Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, today announced key events at the upcoming Society for Vascular Surgery 2018 Vascular Annual Meeting (VAM) June 20-23 at the Hynes Convention Center in Boston. These include real-world data presentations comparing the company’s TransCarotid Artery Revascularization (TCAR) procedure to transfemoral carotid artery stenting (TFCAS) and carotid endarterectomy (CEA), as well as other company-sponsored events about TCAR.
Expanded Phase of Trial will Assess anti-TIGIT in Combination with anti-PD1